DCTH

Business Context and Reporting Period

Company: Delcath Systems, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Stage: Development Stage Company
Overview: Delcath is a specialty pharmaceutical and medical device company focused on oncology. Its proprietary system for chemosaturation therapy is designed to administer high-dose chemotherapy to diseased organs, primarily targeting liver cancers. The company has not yet received FDA or foreign regulatory approval for commercial sale of its system.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss for the nine months ended September 30, 2010, was $31.4 million, a $15.0 million increase compared to $16.4 million in the same period in 2009. This was driven by a $13.1 million increase in total costs.
• Expense Growth:
  • General and Administrative (G&A): Increased by $7.3 million (from $2.1M to $9.4M) due to staffing expansion for commercialization, marketing, sales, and finance.
  • Research and Development (R&D): Increased by $5.8 million (from $6.0M to $11.8M) due to hiring, operational costs at the Queensbury facility, and regulatory preparation.
• Warrant Liability: The company recorded a non-cash gain of $10.2 million from the change in fair value of warrant liabilities, partially offsetting the operating loss. The total warrant liability stood at $12.8 million.
• Employee Count: Full-time employees increased from 10 at the end of Q3 2009 to 44 at the end of Q3 2010.
• Liquidity: Cash and cash equivalents increased from $35.5 million (Dec 31, 2009) to $51.8 million (Sep 30, 2010), primarily due to a public offering in August 2010.

Guidance, Outlook, and Risks

• Regulatory Status: The company initiated a rolling New Drug Application (NDA) submission to the FDA in April 2010 and expected to complete it in Q4 2010. The system is not yet approved for commercial sale.
• Clinical Trials:
  • Concluded a Phase III trial for metastatic melanoma to the liver, meeting the primary endpoint of extended hepatic progression-free survival.
  • Completed a multi-arm Phase II trial for primary and metastatic liver cancer.
  • Plans to conduct a trial with doxorubicin for primary liver cancer in Asia.
• Capital Resources: Management believes current capital is sufficient to fund operations through 2011. The company raised approximately $33.6 million in net proceeds from a public offering in August 2010.
• Strategic Partnerships:
  • Entered a research and distribution agreement with Chi-Fu Trading Co., Ltd. for Taiwan (received $300,000 upfront).
  • Subsequent event (Oct 2010): Entered an agreement with Synerx Pharma and Bioniche for the supply of melphalan hydrochloride.
• Risks: Significant risks include the uncertainty of FDA approval, the need for additional capital to fund development and commercialization, and the potential for the warrant liability to fluctuate based on stock price volatility.

Investor Verification Checklist

• Regulatory Timeline: Verify the status of the NDA submission to the FDA and any potential delays in approval.
• Cash Burn Rate: Confirm the sufficiency of the $51.8 million cash balance to sustain operations through 2011 given the increasing burn rate ($16.9M used in operations for the nine months).
• Warrant Liability: Monitor the fair value of the $12.8 million warrant liability, as fluctuations in stock price will create significant non-cash gains or losses impacting net income.
• Commercialization Readiness: Assess the progress of the manufacturing facility in Queensbury and the hiring of commercial staff.
• Partnership Milestones: Track the fulfillment of conditions for the Chi-Fu Trading agreement (e.g., CE Mark, FDA approval) to unlock remaining milestone payments.